Nutrigenomics
(Not to be confused with Nutrigenetics)
Nutrigenomics is a branch of nutritional genomics and is the study of the effects of foods and food constituents on gene expression.[1]
This means that nutrigenomics is research focusing on identifying and understanding molecular-level interaction between nutrients and other dietary bioactives with the genome. Nutrigenomics has also been described by the influence of genetic variation on nutrition, by correlating gene expression or SNPs with a nutrient's absorption, metabolism, elimination or biological effects. By doing so, nutrigenomics aims to develop rational means to optimise nutrition with respect to the subject's genotype.
By determining the mechanism of the effects of nutrients or the effects of a nutritional regime, nutrigenomics tries to define the causality relationship between these specific nutrients and specific nutrient regimes (diets) on human health. Nutrigenomics has been associated with the idea of personalized nutrition based on genotype. While there is hope that nutrigenomics will ultimately enable such personalised dietary advice, it is a science still in its infancy and its contribution to public health over the next decade is thought to be major.[2]
Whilst nutrigenomics is aimed at developing an understanding of how the whole body responds to a food via systems biology, research into the effect of a single gene/single food compound relationships is known as nutrigenetics.[3]
-----
[1] Rawson, N. (October 24, 2008). Nutrigenomics Boot Camp: Improving Human Performance through Nutrigenomic Discovery. A Supply Side West VendorWorks Presentation. Las Vegas, Nevada
[2] Müller M, Kersten S. (2003). Nutrigenomics: Goals and Perspectives. Nature Reviews Genetics 4. 315 -322.
[3] Astley, Sian B. (Oct 2007). "An introduction to nutrigenomics developments and trends.". Genes Nutr. 2 (1): 11–13. Retrieved Jan 2013.
Researched by:
@mannaglide
http://MannaGoods.blogspot.com
---------
Sunday, August 11, 2013
Monday, August 5, 2013
Natural Remedy-Memory
MEMORY
Gingko Bibloba 500mg/D
Panek/Siberian Ginseng
Vitamin C IV
Vitamin E
Phosphatidylserine 300mg/d
Bacopa 300mg/d
B12 sublingual 400mg/d
Club Moss .2mg/d
Fish Oil 5G/d
Acetyl L-Carnitine 500mg TID
http://ow.ly/1z4ta0
#NaturalRemedies
---------
Gingko Bibloba 500mg/D
Panek/Siberian Ginseng
Vitamin C IV
Vitamin E
Phosphatidylserine 300mg/d
Bacopa 300mg/d
B12 sublingual 400mg/d
Club Moss .2mg/d
Fish Oil 5G/d
Acetyl L-Carnitine 500mg TID
http://ow.ly/1z4ta0
#NaturalRemedies
---------
Thursday, August 1, 2013
The Man Who Cured Heart Disease With a Natural Molecule, 20 Years Before Cholesterol Drugs!
The Man Who Cured Heart Disease With a Natural Molecule, 20 Years Before Cholesterol Drugs!, by Bill Sardi
His name: Dr. Lester Morrison.
His qualifications: Director and Research Professor, Institute for Arteriosclerosis Research, Loma Linda University, School of Medicine
Author: Coronary Heart Disease and the Mucopolysaccharides (1974, Charles C. Thomas)
In 1982 Dr. Morrison wrote: "I am Lester Morrison MD, and I have been a doctor for over 50 years. Much of that time has been devoted to finding a way to stop heart disease, which killed my mother, my father and several other members of my family and remains the number one killer in the U.S. and other developed countries."
Dr. Morrison provided compelling evidence in the 1960s that heart and blood vessel disease could be reversed and prevented with natural molecules, particularly chondroitin sulfate. This was over 20 years prior to the advent of the first cholesterol-reducing statin drug, Mevacor (1987).
Dr. Morrison writes that his ideas involving heart disease went back as far as 1942. He first began is his research using natural molecules to heal damaged hearts and arteries.
Dr. Morrison's research was published in no less than 8 different medical journals. He began his studies in the 1940s, working with choline, a natural component of lecithin.
Here are the results (below) of an early study published in the American Heart Journal. Lecithin was later to become an important component in Dr. Morrison's Heart Saver Program. (Dr. Morrison's book for the lay public by this title can still be purchased.)
Comparison of Survival Rates: Choline (Lecithin)
Patients with coronary thrombosis (blood clots in the heart) after 3 years:
115 patients
Deaths
with choline 14
115 patients Deaths
without choline 35
Source: American Heart Journal, July—August, p. 729, 1949
He later conceived of the idea that gelatinous material, then known as mucopolysaccharides, today known as glycosaminoglycans, could heal damaged hearts and arteries. His work involved chondroitin sulfate, a molecule that is a normal component of the connective tissue in the body. Dr. Morrison calls it "the glue of life."
He noted that chondroitin is the "coronary artery's first line of defense against invasion by foreign substances," such as cholesterol, bacteria and tumor cells. Chondroitin contributes to the elasticity of the blood vessels.
In cross section photos of coronary arteries, Dr. Morrison showed what a coronary artery looked in when an animal was fed a high-fat/cholesterol diet, revealing almost complete obstruction of the artery, and then when chondroitin sulfate was added to animal diets. The artery appears normal.
Heparin is often administered to fresh heart attack patients to inhibit blood clots. The above photos demonstrate the superiority of chondroitin sulfate over heparin. Dr. Morrison said, "chondroitin did the job just as well as heparin, and the effect lasted longer. The anti-clotting property of heparin only lasts about 5 hours. In animal studies, chondroitin prolonged anti-clotting for up to two full days."
It was time for Dr. Morrison to begin treating live human subjects with chondroitin. Here are the startling results of his first studies.
IMPACT OF CHONDROITIN — HEART ATTACK PREVENTION
Heart attacks among patients over 6-year period
Angiology Volume 25, Page 269, 1973
60 patients
Heart attack: fatal- with chondroitin
4
350% Reduction
60 patients
Heart attack/ fatal
no chondroitin
14
60 patients
Nonfatal heart attack-
with chondroitin
0
Total Risk Reduction
60 patients
Nonfatal heart attack-
no chondroitin
10
Dr. Morrison treated 134 patients with chondroitin between 1942 and 1955
"The results were more than good, they were marvelous."
Group 1: coronary arteriosclerotic heart disease
74% improved
Group 2: arteriosclerosis of the brain arteries
77% improved
Group 3: hardening of the arteries of the legs
80% improved
More recent studies confirm Dr. Morrison's earlier findings, that chondroitin sulfate is important in healing following a heart attack. Yet nothing is said of Dr. Morrison's incredible discoveries decades prior.
Case presentations
Convincing evidence is also provided by Dr. Morrison with the presentation of individual cases, treated with chondroitin sulfate. Here is the data presented in three individual subjects.
Case No. 1
Male, age 68
Previous heart attack 1949
Diagnosis in 1965: artery disease, high blood pressure, coronary artery (heart) disease
Multiple cerebro-vascular incidents (impairment of oxygen to the brain, "mini strokes"); visual impairment; disorientation; exhaustion; difficulty speaking; needs assistance to walk or stand; severe vertigo (imbalance); fainting (black outs); blood pressure 170/125; takes 5 drugs and a vitamin pill.
Began 10,000 milligrams of oral chondroitin sulfate in May, 1966, tapered to 3000 mgs after 4 months and 1500 mgs after 5 months. After 2 months, "dramatic persistent improvement noted." All black-outs ceased; remarkable improvement in vision; able to walk without assistance; able to walk 6 miles each morning; notable hair growth.
Case No. 2
Female, age 59
Diagnosis in 1966: coronary artery disease with angina (chest pain); rheumatoid and osteoarthritis
Chest pain radiating to right shoulder for 3 years accompanied by shortness of breath, exhaustion, fright; symptoms relieved by rest; blood pressure 118/74; ankle swelling. Takes vitamin E, lecithin, valium, nitroglycerine, multivitamin, thyroid, arthritis drug.
Began 6000 milligrams of oral chondroitin sulfate in June of 1966, tapered to 1500 mg by December, 1966.
Two months following chondroitin: "very marked clinical improvement; complete disappearance of angina chest pain; began swimming, walking. Remarkable increase in vitality."
Case No. 3
Male, age 77
Diagnosis: Heart attack (healed), general artery disease, high blood pressure, prostate enlargement, "heart pounding" and skipped heartbeats; weakness, shortness of breath on exertion, loss of memory, insomnia, nervousness; blood pressure 160/100.
Previous treatments: Digitalis, blood pressure drugs, lecithin, vitamin supplements.
Began 6000 milligrams of oral chondroitin sulfate in June of 1966, tapered to 1500 mgs by Oct. 1966.
By Sept. 1966 patient reported he "feels wonderful"; disappearance of fatigue, debility, nervousness, weakness on exertion; no skipped heart beats; bushy hair growth on head, black hair replacing white hair; cancellation of planned prostate surgery.
Two recent experiences come to mind in regard to chondroitin sulfate and post-heart attack patients.
A man living in a remote part of eastern Washington State was reported to have experienced crushing persistent chest pain, with swelling of his ankles, evidence of heart failure following a heart attack. The man was averse to seeking medical treatment. He was advised to take 1500 milligrams of chondroitin sulfate with other dietary supplements. Months later he was finally coaxed to undergo examination by a cardiologist who explained, by his past history, he had experienced some sort of serious cardiac event, but that there was no remaining evidence of the event.
In another instance, a 64-year-old man, who had experienced four prior heart attacks, which were evident on his electrocardiogram (EKG), took 1500 milligrams of chondroitin sulfate for a few months, then returned to a follow-up EKG in preparation for hernia surgery. Surprisingly, his EKG showed no evidence of a prior heart attack. The EKG technician thought his name had mistakenly been marked on an EKG of a healthy patient, so the EKG test was repeated, with the same result. This man has no more chest pain and is bicycling and hiking at a performance level uncharacteristic of a person his age.
The heart is slow to heal following a heart attack. Cell renewal is slow. Heart muscle tissue remains scarred (fibrotic). The provision of supplemental chondroitin sulfate appears to accelerate healing following a heart attack and would be a simple and unproblematic approach to regaining heart health following a heart attack. For the healthy, supplemental chondroitin sulfate would keep arterial plaque from developing altogether.
Since chondroitin also inhibits arterial calcification and cholesterol plaque as well as formation of blood clots, it becomes a comprehensive plaque and clot buster, proven in forgotten human studies. Chondroitin sulfate alone should be preferred over glucosamine, which requires a number of nutritional precursors before it can be converted to chondroitin.
References:
Angiology. 1973 May; 24(5):269—87
Coronary heart disease: reduction of death rate by chondroitin sulfate A. Morrison LM, Enrick N.
Experientia. 1972 Dec 15; 28(12):1410—1
Absence of naturally occurring coronary atherosclerosis in squirrel monkeys treated with chondroitin sulfate A. Morrison LM, Bajwa GS.
Atherosclerosis. 1972 Jul—Aug; 16(1):105—18.
Prevention of vascular lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced by a hypervitaminosis D, cholesterol-containing diet. Morrison LM, Bajwa GS, Alfin-Slater RB, Ershoff BH.
Angiology. 1971 Mar; 22(3):165—74
Reduction of ischemic coronary heart disease by chondroitin sulfate A. Morrison LM.
Experimental Medicine Surgery. 1970; 28(2):188—93
Prolongation of the plasma thrombus formation time of dogs administered chondroitin sulfates A and C. Morrison LM, Bajwa GS, Ershoff BH.
J Am Geriatric Society 1969 Oct; 17(10):913—23
Response of ischemic heart disease to chondroitin sulfate-A. Morrison LM.
Experimental Medicine Surgery. 1969; 27(3):278—89
The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: preliminary report. Morrison LM, Branwood AW, Ershoff BH, Murata K, Quilligan JJ Jr, Schjeide OA, Patek P, Bernick S, Freeman L, Dunn OJ, Rucker P.
J American Geriatric Society. 1968 Jul; 16(7):779—85
Treatment of coronary arteriosclerotic heart disease with chondroitin sulfate-A: preliminary report. Morrison LM.
Experimental Medicine Surgery. 1967; 25(1):61—71
Treatment of atherosclerosis with acid mucopolysaccharides. Morrison LM, Quilligan JJ Jr, Murata K, Schjeide OA, Freeman L, Ershoff BH.
Circulation Research. 1966 Aug; 19(2):358—63
Prevention of atherosclerosis in sub-human primates by chondroitin sulfate A. Morrison LM, Murata K, Quilligan JJ Jr, Schjeide OA, Freeman L.
January 28, 2010
Bill Sardi is a frequent writer on health and political topics. His health writings can be found at www.naturalhealthlibrarian.com. He is the author of You Don't Have To Be Afraid Of Cancer Anymore.
Copyright © 2010 Bill Sardi Word of Knowledge Agency, San Dimas, California. This article has been written exclusively for www.LewRockwell.com and other parties who wish to refer to it should link rather than post at other URLs.
Researched by:
@mannaglide
http://MannaGoods.blogspot.com
--------
His name: Dr. Lester Morrison.
His qualifications: Director and Research Professor, Institute for Arteriosclerosis Research, Loma Linda University, School of Medicine
Author: Coronary Heart Disease and the Mucopolysaccharides (1974, Charles C. Thomas)
In 1982 Dr. Morrison wrote: "I am Lester Morrison MD, and I have been a doctor for over 50 years. Much of that time has been devoted to finding a way to stop heart disease, which killed my mother, my father and several other members of my family and remains the number one killer in the U.S. and other developed countries."
Dr. Morrison provided compelling evidence in the 1960s that heart and blood vessel disease could be reversed and prevented with natural molecules, particularly chondroitin sulfate. This was over 20 years prior to the advent of the first cholesterol-reducing statin drug, Mevacor (1987).
Dr. Morrison writes that his ideas involving heart disease went back as far as 1942. He first began is his research using natural molecules to heal damaged hearts and arteries.
Dr. Morrison's research was published in no less than 8 different medical journals. He began his studies in the 1940s, working with choline, a natural component of lecithin.
Here are the results (below) of an early study published in the American Heart Journal. Lecithin was later to become an important component in Dr. Morrison's Heart Saver Program. (Dr. Morrison's book for the lay public by this title can still be purchased.)
Comparison of Survival Rates: Choline (Lecithin)
Patients with coronary thrombosis (blood clots in the heart) after 3 years:
115 patients
Deaths
with choline 14
115 patients Deaths
without choline 35
Source: American Heart Journal, July—August, p. 729, 1949
He later conceived of the idea that gelatinous material, then known as mucopolysaccharides, today known as glycosaminoglycans, could heal damaged hearts and arteries. His work involved chondroitin sulfate, a molecule that is a normal component of the connective tissue in the body. Dr. Morrison calls it "the glue of life."
He noted that chondroitin is the "coronary artery's first line of defense against invasion by foreign substances," such as cholesterol, bacteria and tumor cells. Chondroitin contributes to the elasticity of the blood vessels.
In cross section photos of coronary arteries, Dr. Morrison showed what a coronary artery looked in when an animal was fed a high-fat/cholesterol diet, revealing almost complete obstruction of the artery, and then when chondroitin sulfate was added to animal diets. The artery appears normal.
Heparin is often administered to fresh heart attack patients to inhibit blood clots. The above photos demonstrate the superiority of chondroitin sulfate over heparin. Dr. Morrison said, "chondroitin did the job just as well as heparin, and the effect lasted longer. The anti-clotting property of heparin only lasts about 5 hours. In animal studies, chondroitin prolonged anti-clotting for up to two full days."
It was time for Dr. Morrison to begin treating live human subjects with chondroitin. Here are the startling results of his first studies.
IMPACT OF CHONDROITIN — HEART ATTACK PREVENTION
Heart attacks among patients over 6-year period
Angiology Volume 25, Page 269, 1973
60 patients
Heart attack: fatal- with chondroitin
4
350% Reduction
60 patients
Heart attack/ fatal
no chondroitin
14
60 patients
Nonfatal heart attack-
with chondroitin
0
Total Risk Reduction
60 patients
Nonfatal heart attack-
no chondroitin
10
Dr. Morrison treated 134 patients with chondroitin between 1942 and 1955
"The results were more than good, they were marvelous."
Group 1: coronary arteriosclerotic heart disease
74% improved
Group 2: arteriosclerosis of the brain arteries
77% improved
Group 3: hardening of the arteries of the legs
80% improved
More recent studies confirm Dr. Morrison's earlier findings, that chondroitin sulfate is important in healing following a heart attack. Yet nothing is said of Dr. Morrison's incredible discoveries decades prior.
Case presentations
Convincing evidence is also provided by Dr. Morrison with the presentation of individual cases, treated with chondroitin sulfate. Here is the data presented in three individual subjects.
Case No. 1
Male, age 68
Previous heart attack 1949
Diagnosis in 1965: artery disease, high blood pressure, coronary artery (heart) disease
Multiple cerebro-vascular incidents (impairment of oxygen to the brain, "mini strokes"); visual impairment; disorientation; exhaustion; difficulty speaking; needs assistance to walk or stand; severe vertigo (imbalance); fainting (black outs); blood pressure 170/125; takes 5 drugs and a vitamin pill.
Began 10,000 milligrams of oral chondroitin sulfate in May, 1966, tapered to 3000 mgs after 4 months and 1500 mgs after 5 months. After 2 months, "dramatic persistent improvement noted." All black-outs ceased; remarkable improvement in vision; able to walk without assistance; able to walk 6 miles each morning; notable hair growth.
Case No. 2
Female, age 59
Diagnosis in 1966: coronary artery disease with angina (chest pain); rheumatoid and osteoarthritis
Chest pain radiating to right shoulder for 3 years accompanied by shortness of breath, exhaustion, fright; symptoms relieved by rest; blood pressure 118/74; ankle swelling. Takes vitamin E, lecithin, valium, nitroglycerine, multivitamin, thyroid, arthritis drug.
Began 6000 milligrams of oral chondroitin sulfate in June of 1966, tapered to 1500 mg by December, 1966.
Two months following chondroitin: "very marked clinical improvement; complete disappearance of angina chest pain; began swimming, walking. Remarkable increase in vitality."
Case No. 3
Male, age 77
Diagnosis: Heart attack (healed), general artery disease, high blood pressure, prostate enlargement, "heart pounding" and skipped heartbeats; weakness, shortness of breath on exertion, loss of memory, insomnia, nervousness; blood pressure 160/100.
Previous treatments: Digitalis, blood pressure drugs, lecithin, vitamin supplements.
Began 6000 milligrams of oral chondroitin sulfate in June of 1966, tapered to 1500 mgs by Oct. 1966.
By Sept. 1966 patient reported he "feels wonderful"; disappearance of fatigue, debility, nervousness, weakness on exertion; no skipped heart beats; bushy hair growth on head, black hair replacing white hair; cancellation of planned prostate surgery.
Two recent experiences come to mind in regard to chondroitin sulfate and post-heart attack patients.
A man living in a remote part of eastern Washington State was reported to have experienced crushing persistent chest pain, with swelling of his ankles, evidence of heart failure following a heart attack. The man was averse to seeking medical treatment. He was advised to take 1500 milligrams of chondroitin sulfate with other dietary supplements. Months later he was finally coaxed to undergo examination by a cardiologist who explained, by his past history, he had experienced some sort of serious cardiac event, but that there was no remaining evidence of the event.
In another instance, a 64-year-old man, who had experienced four prior heart attacks, which were evident on his electrocardiogram (EKG), took 1500 milligrams of chondroitin sulfate for a few months, then returned to a follow-up EKG in preparation for hernia surgery. Surprisingly, his EKG showed no evidence of a prior heart attack. The EKG technician thought his name had mistakenly been marked on an EKG of a healthy patient, so the EKG test was repeated, with the same result. This man has no more chest pain and is bicycling and hiking at a performance level uncharacteristic of a person his age.
The heart is slow to heal following a heart attack. Cell renewal is slow. Heart muscle tissue remains scarred (fibrotic). The provision of supplemental chondroitin sulfate appears to accelerate healing following a heart attack and would be a simple and unproblematic approach to regaining heart health following a heart attack. For the healthy, supplemental chondroitin sulfate would keep arterial plaque from developing altogether.
Since chondroitin also inhibits arterial calcification and cholesterol plaque as well as formation of blood clots, it becomes a comprehensive plaque and clot buster, proven in forgotten human studies. Chondroitin sulfate alone should be preferred over glucosamine, which requires a number of nutritional precursors before it can be converted to chondroitin.
References:
Angiology. 1973 May; 24(5):269—87
Coronary heart disease: reduction of death rate by chondroitin sulfate A. Morrison LM, Enrick N.
Experientia. 1972 Dec 15; 28(12):1410—1
Absence of naturally occurring coronary atherosclerosis in squirrel monkeys treated with chondroitin sulfate A. Morrison LM, Bajwa GS.
Atherosclerosis. 1972 Jul—Aug; 16(1):105—18.
Prevention of vascular lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced by a hypervitaminosis D, cholesterol-containing diet. Morrison LM, Bajwa GS, Alfin-Slater RB, Ershoff BH.
Angiology. 1971 Mar; 22(3):165—74
Reduction of ischemic coronary heart disease by chondroitin sulfate A. Morrison LM.
Experimental Medicine Surgery. 1970; 28(2):188—93
Prolongation of the plasma thrombus formation time of dogs administered chondroitin sulfates A and C. Morrison LM, Bajwa GS, Ershoff BH.
J Am Geriatric Society 1969 Oct; 17(10):913—23
Response of ischemic heart disease to chondroitin sulfate-A. Morrison LM.
Experimental Medicine Surgery. 1969; 27(3):278—89
The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: preliminary report. Morrison LM, Branwood AW, Ershoff BH, Murata K, Quilligan JJ Jr, Schjeide OA, Patek P, Bernick S, Freeman L, Dunn OJ, Rucker P.
J American Geriatric Society. 1968 Jul; 16(7):779—85
Treatment of coronary arteriosclerotic heart disease with chondroitin sulfate-A: preliminary report. Morrison LM.
Experimental Medicine Surgery. 1967; 25(1):61—71
Treatment of atherosclerosis with acid mucopolysaccharides. Morrison LM, Quilligan JJ Jr, Murata K, Schjeide OA, Freeman L, Ershoff BH.
Circulation Research. 1966 Aug; 19(2):358—63
Prevention of atherosclerosis in sub-human primates by chondroitin sulfate A. Morrison LM, Murata K, Quilligan JJ Jr, Schjeide OA, Freeman L.
January 28, 2010
Bill Sardi is a frequent writer on health and political topics. His health writings can be found at www.naturalhealthlibrarian.com. He is the author of You Don't Have To Be Afraid Of Cancer Anymore.
Copyright © 2010 Bill Sardi Word of Knowledge Agency, San Dimas, California. This article has been written exclusively for www.LewRockwell.com and other parties who wish to refer to it should link rather than post at other URLs.
Researched by:
@mannaglide
http://MannaGoods.blogspot.com
--------
Subscribe to:
Posts (Atom)